Role of systemic corticosteroids in preventing hypoxia among patients with mild COVID-19 : An observational study
Use of systemic corticosteroids is well-established in COVID-19 patients with hypoxia; however, there is scant data on its role in patients with mild disease and prolonged symptoms as a measure to prevent disease progression. The aim of this study is to evaluate the role of systemic corticosteroids in preventing hypoxia (SpO2 ≤ 93% on room-air) among mild COVID-19 patients. An observational study was conducted among symptomatic COVID-19 patients taking oral corticosteroids and attending institute teleconsultation facility between 10th-30th June 2021. Patients who were already on corticosteroids for other indication or required oxygen supplementation before or within 24-hours of initiation of corticosteroids were excluded. A total of 140 consecutive symptomatic COVID-19 patients were included. Higher baseline C-reactive protein (OR: 1.03, 95% CI: 1.02-1.06, p < 0.001) and early systemic corticosteroid (within 7 days) initiation (OR: 6.5, 95% CI: 2.1-20.1, p = 0.001) were independent risk factors for developing hypoxia (SpO2 ≤ 93%). Progression to hypoxia was significantly higher in patients who received corticosteroids before day 7 of illness (36.7%, 95% CI, 23.4-51.7%) compared to ≥ 7 of illness (14.3%, 95% CI, 7.8-23.2%) for persistent fever. Systemic corticosteroids within 7 days from symptom-onset were harmful and increased the risk of progression to hypoxia, whereas it may decrease the risk of progression when administered on or beyond 7 days in patients with mild COVID-19 and persistent symptoms. A well-designed randomised controlled trial is required to validate the findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Drug discoveries & therapeutics - 15(2021), 5 vom: 21. Nov., Seite 273-277 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aggarwal, Anivita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 26.11.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5582/ddt.2021.01081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332453650 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332453650 | ||
| 003 | DE-627 | ||
| 005 | 20231225215616.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5582/ddt.2021.01081 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332453650 | ||
| 035 | |a (NLM)34707019 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aggarwal, Anivita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of systemic corticosteroids in preventing hypoxia among patients with mild COVID-19 |b An observational study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.11.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Use of systemic corticosteroids is well-established in COVID-19 patients with hypoxia; however, there is scant data on its role in patients with mild disease and prolonged symptoms as a measure to prevent disease progression. The aim of this study is to evaluate the role of systemic corticosteroids in preventing hypoxia (SpO2 ≤ 93% on room-air) among mild COVID-19 patients. An observational study was conducted among symptomatic COVID-19 patients taking oral corticosteroids and attending institute teleconsultation facility between 10th-30th June 2021. Patients who were already on corticosteroids for other indication or required oxygen supplementation before or within 24-hours of initiation of corticosteroids were excluded. A total of 140 consecutive symptomatic COVID-19 patients were included. Higher baseline C-reactive protein (OR: 1.03, 95% CI: 1.02-1.06, p < 0.001) and early systemic corticosteroid (within 7 days) initiation (OR: 6.5, 95% CI: 2.1-20.1, p = 0.001) were independent risk factors for developing hypoxia (SpO2 ≤ 93%). Progression to hypoxia was significantly higher in patients who received corticosteroids before day 7 of illness (36.7%, 95% CI, 23.4-51.7%) compared to ≥ 7 of illness (14.3%, 95% CI, 7.8-23.2%) for persistent fever. Systemic corticosteroids within 7 days from symptom-onset were harmful and increased the risk of progression to hypoxia, whereas it may decrease the risk of progression when administered on or beyond 7 days in patients with mild COVID-19 and persistent symptoms. A well-designed randomised controlled trial is required to validate the findings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a hypoxia | |
| 650 | 4 | |a prolonged fever | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 700 | 1 | |a Mittal, Ankit |e verfasserin |4 aut | |
| 700 | 1 | |a Soneja, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Shankar, Sujay Halkur |e verfasserin |4 aut | |
| 700 | 1 | |a Naik, Shivdas |e verfasserin |4 aut | |
| 700 | 1 | |a Kodan, Parul |e verfasserin |4 aut | |
| 700 | 1 | |a Nischal, Neeraj |e verfasserin |4 aut | |
| 700 | 1 | |a Jorwal, Pankaj |e verfasserin |4 aut | |
| 700 | 1 | |a Ray, Animesh |e verfasserin |4 aut | |
| 700 | 1 | |a Wig, Naveet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug discoveries & therapeutics |d 2007 |g 15(2021), 5 vom: 21. Nov., Seite 273-277 |w (DE-627)NLM193136589 |x 1881-784X |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2021 |g number:5 |g day:21 |g month:11 |g pages:273-277 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5582/ddt.2021.01081 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2021 |e 5 |b 21 |c 11 |h 273-277 | ||